Soluble Therapeutics Acquired by CytoBioscience more

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) more

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA more

Robotics: Germ-Zappers Are Saving Lives more

DHR first in RGV with xenon UV disinfection systems more

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots more

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Cardiovate Develops First Bioabsorbable Vascular Graft more

Funding San Antonio’s Biotech Ecosystem more

A biotech groups to share in major military contract to manufacture stem cells more

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Robots show Marin, Sonoma hospitals the light on disinfection more

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

SA biotech firm drawing global interest year after moving from Germany more

TFS Corporation makes bond offer more

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

HOUSTON, Aug. 4, 2016 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced the award of a $2 million research grant from the FDA's Office of Orphan Products Development to support its Phase 2 clinical trial evaluating DNX-2401 with the checkpoint inhibitor pembrolizumab for patients with recurrent glioblastoma.

This FDA grant program supports the development of medicines for rare diseases or conditions where no current therapy exists. Approximately 100 applications are received per year from which roughly 10 are selected for funding following rigorous scientific review.

DNX-2401 is a potent oncolytic adenovirus that targets and kills cancer cells, while leaving normal cells intact. Multiple clinical studies in patients with recurrent glioblastoma and gynecologic cancer have shown that DNX-2401 has a favorable safety profile, strong tumor-killing potential and can trigger an antitumor immune response. DNX-2401 has already received Orphan Drug Designation and Fast Track Designation by the FDA and PRIME Designation by the EMA. 

Frank Tufaro, Ph.D., Chief Executive Officer of DNAtrix said, "We are delighted by the FDA's continued recognition of DNX-2401 as a promising treatment for glioblastoma by awarding this grant to further support our product development strategy. This is an important accomplishment for the company and another significant step toward bringing DNX-2401 to patients with devastating brain tumors."

For more information about this study, please refer to Clinicaltrials.gov (NCT02798406).

About DNX-2401 in Glioblastoma
DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer, with glioblastoma as the initial indication. Glioblastoma is the most aggressive form of brain cancer, which has a median survival of 15 months following a patient's initial diagnosis. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process can also trigger an anti-tumor immune response. DNX-2401 is currently being investigated in several clinical studies and has been well tolerated in all settings.

Compelling results from clinical studies in recurrent glioblastoma indicate that DNX-2401 can (1) replicate in human brain tumors for a period of weeks to months, (2) trigger immune cell infiltration into the tumor, (3) cause ongoing tumor destruction and (4) induce durable responses to therapy. In these studies, patient survival has been prolonged, including in those achieving a complete response.

About DNAtrix
DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at http://www.DNAtrix.com.

Contact                 
DNAtrix
Imran Alibhai, Ph.D.
SVP Business Development
ialibhai@dnatrix.com
 
Source: http://www.prnewswire.com back

TFS Corporation - July 2016 Update more

StemBioSys reaches European distribution agreement for its products more

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

DNAtrix Receives European Medicines Agency PRIME Designation more

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

Australia forestry company TFS Corp gets two ratings upgrades more

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

StemBioSys reaches distribution agreement for its products in South Korea more

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

Texas among top states in foreign investments more

How Your Family Drives Business Decisions more

StemBioSys enters distribution agreement for its products in Japan more

San Antonio biotech firm takes big step toward global expansion more

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

This hospital spent $300,000 on giant, superbug-killing robots more

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

Bexar County added 4,350 jobs last year, study says more

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

San Antonio venture capital funding fell last year more

neoSurgical Limited Expands Indications For neoClose Device more

Bio2 Medical Closes Series D Preferred Stock more

TFS undertakes $60 million placement more

Bluegrass Vascular Technologies’ catheter system used on first patient more

Cytocentrics refunds $100,000 in economic development funds to city more

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

Long-term acute care facility in California implements Xenex germ-zapping robot more

Robotic housekeeper disinfects the rooms at Modesto hospital more

Aerin Medical raises $16.7M, adds new board members more

Brokers Sniff Sweet Potential In TFS Corp more

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

TFS Corporation - January 2016 Update more

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Strategic partnering deal with Cytocentrics more

Cytocentrics CEO: San Antonio to get big boost from new deal more

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema more

Santalis announces positive results for pediatric atopic dermatitis treatment more

Here’s why the TFS Corporation Limited share price soared 28% today more

Cytocentrics gaining traction in San Antonio more

The Drugstore Acne Fighters Dermatologists Swear By more

neoSurgical® Begins Postmarket Surveillance Study more

Santalis Announces First Subject Enrolled in Phase 2 Trial more

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more